Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT).
Crizotinib
Inflammatory myofibroblastic tumor (IMT)
Lorlatinib
RNA sequencing
ROS1
Tyrosine kinase inhibitors (TKI)
Journal
Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
18
04
2021
revised:
15
05
2021
accepted:
22
05
2021
pubmed:
2
6
2021
medline:
4
8
2021
entrez:
1
6
2021
Statut:
ppublish
Résumé
Here, we present the case of an adolescent with a rare metastatic Inflammatory myofibroblastic tumor (IMT) harboring a TFG-ROS1 fusion initially detected on tumor progression and retrospectively identified in the primary tumor after targeted RNA sequencing. The patient benefitted from sequential TKIs over a 5-year period with response to the third generation ALK/ROS inhibitor, lorlatinib leading to resection of the primary tumor. Detailed molecular analysis can identify targetable oncogenic kinase fusions that alters management in patients with unresectable disease and should be considered in all patients.
Identifiants
pubmed: 34059352
pii: S0169-5002(21)00404-9
doi: 10.1016/j.lungcan.2021.05.024
pii:
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Proteins
0
Proto-Oncogene Proteins
0
TFG protein, human
0
Protein-Tyrosine Kinases
EC 2.7.10.1
ROS1 protein, human
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
151-155Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Copyright © 2021. Published by Elsevier B.V.